Chapter 14 Myasthenia Gravis: A Clinical Trials Perspective

Blue Books of Practical Neurology

Volumn 25, Issue C, 2001, Pages 293-310

  Pascuzzi, Robert M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77957117241     PISSN: 18773419     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1877-3419(09)70021-2     Document Type: Article

References (47)

1. Howard Jr. F.M., Lenin V.A., Finley J., et al. Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis. Ann N Y Acad Sci 505 (1987) 526-538
2. Lacquer L., and Weigert C. Beitrage zur Lehre von der Erb'schen krankheit ueber die Erb-sche krankheit (myasthenia gravis). Neurol Zentralblatt 20 (1901) 594-601
3. Grob D., Arsura E.L., Brunner N.G., and Namba T. The course of myasthenia gravis and therapies affecting outcome. Ann N Y Acad Sci 505 (1987) 472-499
4. Walker M.B. Case showing the effect of prostigmin on myasthenia gravis. Proc R Soc Med 28 (1935) 759-761
5. Walker M.B. Myasthenia gravis: a case in which fatigue of the forearm muscles could induce paralysis of the extraocular muscles. Proc R Soc Med 31 (1937) 722
6. Blalock A., Mason M.F., Morgan H.J., and Riven S.S. Myasthenia gravis in tumors of the thymic region. Report of a case in which tumor was removed. Ann Surg 110 (1939) 544-561
7. Kennedy F.S., and Moersch F.P. Myasthenia gravis: a clinical review of 87 cases observed between 1915 and the early part of 1932. Can Med Assoc J 37 (1937) 217
8. Oosterhuis H.J.G.H. The natural course of myasthenia gravis: a long term follow up study. J Neurol Neurosurg Psychiatry 52 (1989) 1121-1127
9. Bever Jr. C.T., Aquino A.V., Penn A.S., et al. Prognosis of ocular myasthenia. Ann Neurol 14 (1983) 516-519
10. Simpson J.A. Myasthenia gravis: a personal view of pathogenesis and mechanism, Part 1. Muscle Nerve 1 (1978) 45-46
11. Howard F.M., Duane D.D., Lambert E.H., and Daube J.R. Alternate-day prednisone: preliminary report of a double-blind controlled study. Ann N Y Acad Sci 274 (1976) 596-607
12. Patten B.M. Myasthenia Gravis: Patho-physiology and Management. Ann N Y Acad Sci 377 (1981) 742 (Referenced as an article discussant). Keesey J, Buffkin D, Kebo D, et al. Plasma Exchange Alone as Therapy for Myasthenia Gravis. In D Grob (ed)
13. Blalock A. Thymectomy in the treatment of myasthenia gravis. Report of 20 cases. J Thorac Surg 13 (1944) 316-339
14. Perlo V.P., Arnason B., Poskanzer D., et al. The role of thymectomy in the treatment of myasthenia gravis. Ann N Y Acad Sci 183 (1971) 308-315
15. Buckingham J.M., Howard F.M., Bernatz P.E., et al. The value of thymectomy in myasthenia gravis: computer assisted match study. Ann Surg 184 (1976) 453-458
16. Eaton L.M., and Clagett O.T. Thymectomy in the treatment of myasthenia gravis. Results in 72 cases compared with 142 cases. JAMA 142 (1950) 963-967
17. Jaretzki A., Pen A.S., Younger D.S., et al. Maximal thymectomy for myasthenia gravis. J Thorac Cardiovasc Surg 95 (1988) 747-757
18. Jaretzki A. Thymectomy for myasthenia gravis: analysis of the controversies regarding technique and results. Neurology 48 4 (1997) 52S-63S
19. Masoaka A., Negaoka Y., and Kotake Y. Distribution of thymic tissue in the anterior mediastinum: current procedures in thymectomy. J Thorac Cardiovasc Surg 70 (1975) 747-754
20. Pirskanen R., Matell G., and Henze A. Results of transsternal thymectomy after failed transcervical thymectomy. Ann N Y Acad Sci 505 (1987) 866-867
21. Schumm J.F., Wietholter H., Fateh-Moghadam A., and Dichgans J. Thymectomy in myasthenia with pure ocular symptoms. J Neurology Neurosurg Psychiatry 48 (1985) 332-337
22. Olanow C.W., Lane R.J.M., and Roses A.D. Thymectomy in late onset myasthenia gravis. Arch Neurol 39 (1982) 82-83
23. Gronseth G.S., and Barohn R.J. Practice parameter: Thymectomy for autoimmune myasthenia gravis (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 55 (2000) 7-15
24. Jaretzki A., Barohn R.J., Ernstoff R.M., et al. Myasthenia gravis. Recommendations for clinical research standards. Neurology 55 (2000) 16-23
25. Kupersmith M.J., Moster M., Bhuiyan S., et al. Beneficial effects of corticosteroids on ocular myasthenia gravis. Arch Neurol 53 (1996) 802-804
26. McQuillen M.P. Ocular myasthenia gravis. Arch Neurol 54 (1997) 229
27. Mount F.W. Corticotropin in the treatment of ocular myasthenia. Arch Neurol 11 (1964) 114-124
28. Howard FM. Personal communication. 1998
29. Mertens H.G., Balzereit F., and Leipert M. The treatment of severe myasthenia gravis with immunosuppressive agents. Eur Neurol 2 (1969) 323-339
30. Matell G., Bergstrom K., Franksson C., et al. Effects of some immunosuppressive procedures on myasthenia gravis. Ann N Y Acad Sci 274 (1979) 659-676
31. Scherpbier H.J., and Oosterhuis H.J. Factors influencing the relapse risk at steroid dose reduction to myasthenia gravis. Clin Neurol Neurosurg 89 (1987) 145-150
32. Hohlfeld R., Toyka K.V., Besinger U.A., et al. Myasthenia gravis: reactivation of clinical disease and of autoimmune factors after discontinuation of long-term azathioprine. Ann Neurol 17 (1985) 238-242
33. Miano M.A., Bosley T.M., Heiman-Patterson T.D., et al. Factors influencing outcome of prednisone dose reduction in myasthenia gravis. Neurology 41 (1991) 919-921
34. Myasthenia Gravis Clinical Study Group. A randomized clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis. J Neurol Neurosurg Psychiatry 56 (1993) 1157-1163
35. Palace J., Newsome-Davis J., Lecky B., and the Myasthenia Study Group. A multicenter randomized double-blind trial of prednisolone plus azathioprine versus prednisolone plus placebo in myasthenia gravis. Neurology 46 (1996) A332
36. Palace J., Newsome-Davis J., Lecky B., and the Myasthenia Gravis Study Group. A randomized doubleblind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 50 6 (1998) 1778-1783
37. Tindall R., Rollins J.A., Phillips J.T., et al. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 316 (1987) 719-724
38. Tindall R., Phillips J.T., Rollins J.A., et al. A clinical therapeutic trial of cyclosporin in myasthenia gravis. Ann N Y Acad Sci 681 (1993) 539-551
39. Goulon M., Elkharrat D., Lokiec F., and Gajdos P. Results of a One Year Open Trial of Cyclosporine in 10 Patients with Severe Myasthenia Gravis. In: Kahan B.D. (Ed). Cyclosporine Applications in Autoimmune Diseases (1988), Grune and Stratton, Philadelphia 211-217
40. Ronager J, Ravnborg M, Vorstrup S Clinical effect of high-dose intravenous immunoglobulin compared to plasma exchange in patients with moderate to severe myasthenia gravis. American Academy of Neurology 51st Annual Meeting. Scientific Program: Scientific Sessions. 1999; 52(6)S:184-185
41. Gajdos P., Chevret S., Clair B., et al. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol 41 6 (1997) 789-796
42. Qureshi A.I., Choundry M.A., Akbar M.S., et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 52 (1999) 629-632
43. Thomas C.E., Mayer S.A., Gungor Y., et al. Myasthenic crisis: clinical features, mortality, complications and risk factors for prolonged intubation. Neurology 48 5 (1997) 1253-1260
44. Berrouschot J., Baumann I., Kalischewski P., et al. Therapy of myasthenic crisis. Crit Care Med 25 7 (1997) 1228-1235
45. Barohn R.J., McIntire D., Herbelin L., et al. Reliability testing of the quantitative myasthenia score. Ann N Y Acad Sci 841 (1998) 769-772
46. Barohn RJ. How to administer the quantitative myasthenia test. Manual and video available through the Myasthenia Gravis Foundation of America, 1996
47. Wolfe G.I., Herbelin J.R., Nations S.P., et al. Myasthenia gravis activities of daily living profile. Neurology 52 7 (1999) 1487-1489